Health Economics›Thyroid cancer medullary›Advanced or metastatic disease iodine-refractory

Advanced or metastatic disease iodine-refractory

Thyroid cancer medullary · 2 regimens

Cost estimates only — modelled on a typical patient (BSA 1.7 m², 70 kg, CrCl 90 mL/min) using the cheapest available formulary presentation. Excludes vial wastage, facility fees, supportive care, and infusion consumables. Not for billing, formulary decisions, or clinical use.

Filters

Y-axis

Cost vs Efficacy · 2 points

Fully pricedPartial pricing

Regimen	Biomarker	Cost/cycle ↓	Cycle	PFS ↕	OS ↕	Est. cycles	Course cost ↕	Evidence
Axitinib monotherapy Variant #01	—	R 21 402	28d	~9.2 mo	~20.9 mo	~2	~R 42 804 PFS proxy · indirect	4
Sunitinib monotherapy Variant #01	—	R 15 867	42d	~8.3 mo	~32.4 mo	~2	~R 31 733 PFS proxy · indirect	36

2 of 2 regimens shown